Section 4 of 6
Clinical evidence
109 evidence topics · 27 sources
Study summaries
INSPIRE
Objective
Location and study date
Study status and dates
| Registry field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Start date, actual | “2023-12-11” |
| Primary completion, actual | “2026-04-14” |
| Completion, actual | “2026-05-19” |
| Enrollment, actual | “165” |
Posted results
No evidence found.
Study design
Randomized, double-blind, placebo-controlled design with open-label extension
Registry design fields
| Design field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Parallel” |
| Masking | “Quadruple” |
| Primary purpose | “treatment” |
| Phase | “Phase 3” |
Eligibility criteria
Diagnosis and age
Hepatic and dermatologic exclusions
Exclusion of prior dersimelagon and other investigational therapy
Erythrocyte protoporphyrin threshold for entry
No evidence found.
Treatment
Dose, route, and frequency
Restriction on zinc oxide sunscreen during treatment
Study outcomes
Rationale for using average daily sunlight exposure time to first prodromal symptom as the primary endpoint
Registered definition of the primary outcome measure
Registered secondary outcome measures
How participants were instructed to generate the endpoint
Regulatory precedent for sunlight-exposure time as a clinically meaningful endpoint
“Accurately tracking sunlight exposure is important for evaluating new therapies and pain-free light exposure time is the precedented, clinically meaningful endpoint used to support afamelanotide's marketing authorization in the US and European Union.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Balance of baseline characteristics between arms
Tabulated baseline characteristics
No evidence found.
Efficacy results
Result at the registered Week 16 timepoint
Responder analyses reported at the congress presentation
Phototoxic reactions occurring without a preceding prodrome
Confidence intervals for the reported effect estimates
No evidence found.
Health-related quality of life and patient-reported outcomes
Other patient-reported outcome instruments
No evidence found.
Safety results
Overall tolerability and most common adverse events
Serious adverse event of malignant melanoma in situ
Discontinuations
Cumulative exposure in the development program
Study limitations
Summary: limitations of the INSPIRE evidence base
No results have been posted to ClinicalTrials.gov, the EU Clinical Trials Information System, or the Japan Registry of Clinical Trials, and no peer-reviewed publication exists. No protocol, statistical analysis plan, analysis-set definition, sample-size calculation, or multiplicity strategy is public, and no confidence interval has been published for any endpoint. Disposition, baseline characteristics, and complete adverse event tables are not available, and no results are reported separately for erythropoietic protoporphyria compared with X-linked protoporphyria or for the adolescent subgroup. The company reports the primary analysis over Weeks 12 to 16, whereas the registered primary outcome measure is at Week 16; the presenter reported that time to prodrome was similar between groups at Week 16 alone. Skin pigmentation is a pharmacologic effect of the drug, and in the phase 2 trial most participants correctly identified their assigned treatment, so blinding was incomplete. Participants were required to expose themselves to sunlight until symptoms developed, which may select for less severely affected individuals.
Functional unblinding by treatment-induced pigmentation
“Likewise, in the phase II trial investigating dersimelagon, 97% of the patients in the low dose group, 100% of the patients in the high dose group and 59% of the patients in the placebo group correctly guessed their treatment allocation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the approval procedures of afamelanotide, the EMA assessed that the lack of complete blinding of the trials impaired the validity of the evidence for efficacy, but also acknowledged that there was no possibility of blinding the studies appropriately” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent commentary on blinding and selection
MT-7117-G01
Objective
Location and study date
Study status and dates
| Registry field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Start date, actual | “2020-06-01” |
| Primary completion, actual | “2021-12-14” |
| Completion, actual | “2022-07-26” |
| Enrollment, actual | “184” |
Participants enrolled by country
Study design
Registry design fields
| Design field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Parallel” |
| Masking | “Triple” |
| Primary purpose | “treatment” |
| Phase | “Phase 3” |
Eligibility criteria
Age, diagnosis, and body weight
Hepatic, dermatologic, and renal exclusions
Prohibited prior and concomitant therapy
Treatment
Tablet strength and number of tablets per arm
Disclosed dose amounts
No evidence found.
Study outcomes
Rationale for using average daily sunlight exposure time to first prodromal symptom as the primary endpoint
Definition of the primary efficacy endpoint and its averaging window
Secondary efficacy endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Number screened and screen failures
No evidence found.
Baseline characteristics
Age distribution and sex
| Characteristic | Placebo | MT-7117 low dose | MT-7117 high dose | Total |
|---|---|---|---|---|
| Adolescents aged 12 to 17 years | “12” | “13” | “12” | “37” |
| Adults aged 18 to 65 years | “47” | “45” | “46” | “138” |
| Older than 65 years | “2” | “5” | “2” | “9” |
| Age in years, arithmetic mean (standard deviation) | “34.1 ( 15.6” | “33.5 ( 17.1” | “34.4 ( 15.3” | “184” |
| Female | “30” | “30” | “33” | “93” |
| Male | “31” | “33” | “27” | “91” |
Baseline disease characteristics, including diagnosis split and protoporphyrin concentrations
No evidence found.
Efficacy results
Primary endpoint: change from baseline in average daily sunlight exposure time to first prodromal symptom at Week 26
Sponsor description of the primary endpoint outcome
Secondary endpoint: total number of sunlight-induced pain events over 26 weeks
Secondary endpoint: responder rate using the 66-minute within-subject meaningful change
Independent characterization of the trial outcome
“The first published phase II trial results demonstrated effectiveness,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“while the phase III trial did not meet its primary efficacy endpoint” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Safety results
Deaths and serious adverse events by period and arm
| Group | Deaths, affected of at risk | Serious adverse events, affected of at risk |
|---|---|---|
| Double-blind treatment, placebo | “0” | “0” |
| Double-blind treatment, MT-7117 low dose | “0” | “2” |
| Double-blind treatment, MT-7117 high dose | “1” | “2” |
| Double-blind extension, placebo to low dose | “0” | “2” |
| Double-blind extension, placebo to high dose | “0” | “1” |
| Double-blind extension, MT-7117 low dose | “0” | “1” |
| Double-blind extension, MT-7117 high dose | “0” | “2” |
Non-serious adverse events reported at the 5% threshold during double-blind treatment
| MedDRA preferred term | Placebo | MT-7117 low dose | MT-7117 high dose |
|---|---|---|---|
| Nausea | “4” | “4” | “17” |
| Headache | “3” | “8” | “9” |
| Diarrhoea | “1” | “5” | “8” |
| Melanocytic naevus | “1” | “6” | “8” |
| Skin hyperpigmentation | “1” | “3” | “8” |
| Skin discolouration | “0” | “5” | “6” |
| Ephelides | “1” | “3” | “4” |
| Photosensitivity reaction | “6” | “1” | “2” |
| Porphyria non-acute | “5” | “1” | “1” |
| Alanine aminotransferase increased | “1” | “3” | “0” |
| Aspartate aminotransferase increased | “1” | “4” | “0” |
| Gamma-glutamyltransferase increased | “5” | “3” | “1” |
Serious adverse events by term
Study limitations
Summary: interpretation of the first phase 3 trial
The trial did not meet its primary endpoint at either dose. Type I error was controlled by a fixed-sequence procedure in which the high dose was tested first; because that comparison was not statistically significant, testing stopped, and every subsequent P value, including those for the low dose, the Patient Global Impression of Change, and the pain-event count, is nominal and descriptive rather than confirmatory. The pre-specified 66-minute responder analysis was negative at both doses, and the placebo group improved by 20.59 minutes, a change of similar magnitude to the treatment differences observed. The sample size was calculated to detect a treatment difference of 52 to 57 minutes, and the observed differences were 9.8 minutes at the low dose and 22.7 minutes at the high dose. One death occurred, from cholestasis in the high-dose arm, the only death reported anywhere in the dersimelagon program in these disorders; the investigator assessed it as probably related to study drug and the sponsor as unlikely or unrelated, and an institutional review board suspended dosing at United States sites from July 14 to July 20, 2021. Two further serious hepatic enzyme elevations occurred in participants switching from placebo to active drug in the extension period. The actual dose amounts are redacted in every public document, no peer-reviewed publication exists, and no baseline disease characteristics, diagnosis subgroup, adolescent subgroup, or exploratory endpoint results have been posted. The sponsor reported no limitations in its results summary.
Limitations declared by the sponsor
Independent critique of the prodromal-symptom endpoint
“The trials investigating dersimelagon use “time to prodrome” as their primary efficacy outcome measure. Prodromal symptoms are a newly introduced concept of early warning signals for a phototoxic reaction such as itching, tingling, burning and stinging.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, in their study, 76% of the participants reported having recovery times of one up to five days after experiencing a prodrome, and 46% experienced pain despite immediately exiting the sun.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with our assessment, phototoxic pain events were observed in all treatment arms in the phase II trial investigating dersimelagon, i.e., in the placebo, low dose and high dose treatment groups [ 52 ]. Therefore, the endpoint “time to prodrome” does not prevent participants from developing severe reactions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ENDEAVOR
Objective
Location and study date
Study status and dates
| Registry field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Start date, actual | “2018-07-05” |
| Primary completion, actual | “2019-09-28” |
| Completion, actual | “2019-09-28” |
| Enrollment, actual | “102” |
Study design
Absence of an open-label extension
No evidence found.
Eligibility criteria
Hepatic, dermatologic, and renal exclusions
Prohibited prior and concomitant therapy
Treatment
Study outcomes
Rationale for using average daily time to first prodromal symptom as the primary endpoint
Clinical rationale for a prodromal-symptom endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics of the randomized population
Efficacy results
Primary endpoint result
“The mean daily time to the first prodromal symptom associated with sunlight exposure increased significantly with dersimelagon: the least-squares mean difference from placebo in the change from baseline to week 16 was 53.8 minutes in the 100-mg dersimelagon group (P = 0.008) and 62.5 minutes in the 300-mg dersimelagon group (P = 0.003).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Unadjusted change from baseline by arm
| Outcome measure, change from baseline to Week 16, minutes | MT-7117 low dose | MT-7117 high dose | Placebo |
|---|---|---|---|
| Average daily time to first prodromal symptom, mean | “74.7” | “92.4” | “21.0” |
| Average daily time to first prodromal symptom, standard deviation | “76.8” | “100” | “63.4” |
| Average daily duration of sunlight exposure without prodromal symptoms, mean | “72.6” | “86.1” | “19.9” |
Consistency of effect across seasons and geographic regions
Health-related quality of life and patient-reported outcomes
Exit questionnaire responses
“Additionally, an online questionnaire assessing quality of life was completed by 75 of the 102 patients enrolled. Of those taking dersimelagon 100 mg, 57.6% rated their EPP as “very much better” and 69.7% rated they were “much more often” able to be outside at the end of the study. Likewise, among those who used dersimelagon 300 mg, positive ratings were given by 48.6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Posted PROMIS-57 and Patient Global Impression of Change results
No evidence found.
Safety results
Non-serious adverse events reported at the 3% threshold
| MedDRA preferred term | MT-7117 low dose | MT-7117 high dose | Placebo |
|---|---|---|---|
| Nausea | “5” | “16” | “4” |
| Ephelides | “5” | “11” | “0” |
| Skin hyperpigmentation | “3” | “11” | “0” |
| Headache | “6” | “10” | “6” |
| Diarrhoea | “4” | “8” | “4” |
| Melanocytic naevus | “4” | “7” | “3” |
| Fatigue | “1” | “6” | “1” |
| Photosensitivity reaction | “5” | “5” | “3” |
| Skin discolouration | “1” | “3” | “0” |
| Urticaria | “0” | “2” | “0” |
| Hepatic enzyme increased | “1” | “0” | “0” |
| Anaphylactic reaction | “1” | “0” | “0” |
Discontinuations and the serious adverse event causality assessment
“Participation in the trial was discontinued by four patients in the placebo group (voluntary withdrawal), two patients in the 100 mg dersimelagon group (one for nonadherence and one for a serious adverse event), and four patients in the 300 mg dersimelagon group (one voluntary withdrawal, two withdrawals for adverse events, and one withdrawal for clinically significant lichen planus found during nevi assessment). The serious adverse event that led to discontinuation by one patient in the 100 mg dersimelagon group was an anaphylactic reaction that was deemed by the investigators to be unrelated to dersimelagon” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limitations of the phase 2 trial
The trial enrolled adults only, was conducted entirely in the United States, and 98 of 102 participants were White with no Black participants. There was no formal power calculation and no multiplicity adjustment across three registered primary outcome measures and seven secondary endpoints, and the registry posts no confidence intervals or P values for any outcome. Sex was unevenly distributed, with 25 of 34 participants female in the high-dose arm compared with 13 of 35 in the placebo arm. Blinding was incomplete because the drug increases skin pigmentation. The erythrocyte protoporphyrin and seasonal subgroup analyses were post hoc. The larger phase 3 trial that followed, using the same primary endpoint at Week 26, did not reproduce the effect size observed here.
Incomplete blinding and absence of a power analysis
“Additionally, there was incomplete blinding in this trial due to increases in skin pigmentation when taking dersimelagon, which allowed many subjects to correctly guess if they were assigned to the active drug group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the phase 2 trial, limitations included a lack of formal statistical power analysis, although such limitations are common in studies of rare diseases such as EPP/XLP” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Critique of the prodromal-symptom endpoint and of placebo control
“Recognizing the seriously harmful consequences of daylight exposure for EPP patients, investigators in the dersimelagon trial specified endpoints in terms of minutes of exposure before the appearance of prodromal symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further, the tingling and itching is not always present. At times, the phototoxic reaction directly starts with the pain, or with a combination of milder symptoms and pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further, being melanocortin receptor agonists, afamelanotide and dersimelagon both increase skin pigmentation and cause partial unblinding of the trial participants in the active treatment group – thus undermining the rationale for the use of placebo controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MT-7117-A-301
Objective
Location and study date
Study title, status, and dates
| Registry field | Quoted record |
|---|---|
| Official title | “A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)” |
| Overall status | “Active, not recruiting” |
| Start date, actual | “2021-08-10” |
| Primary completion, estimated | “2027-12” |
| Enrollment, actual | “286” |
Study design
Open-label single-group design
| Design field | Quoted record |
|---|---|
| Allocation | “na” |
| Intervention model | “Single group” |
| Masking | “None” |
| Phase | “Phase 3” |
Relationship to the other trials in the program
Eligibility criteria
Rollover eligibility from the phase 3 trials
Hepatic and dermatologic exclusions
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Safety outcome measures and observation period
Absence of efficacy endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled
| Registry field | Quoted record |
|---|---|
| Enrollment, actual | “286” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Not applicable.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary: status of the long-term extension
The study is open-label and single-group, so it provides no controlled comparison. It remains ongoing with estimated completion in December 2027, and no results have been posted to ClinicalTrials.gov or the EU Clinical Trials Register. Enrollment is restricted to participants who completed one of the two phase 3 trials or a previous period of the extension itself, which excludes participants from the phase 2 trial and selects for people who tolerated and continued earlier treatment.
MT-7117-E01
Objective
Purpose of the first-in-human study
“In this double-blind, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of dersimelagon in healthy participants were evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
No evidence found.
Study design
Single and multiple ascending dose design
“In this double-blind, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of dersimelagon in healthy participants were evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
No evidence found.
Treatment
Doses administered
“No treatment-related effects on melanin density (MD) were observed following single doses of dersimelagon; however, after multiple doses, increases in MD were observed in participants receiving 150 and 300 mg dersimelagon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using melanin density as a pharmacodynamic endpoint
Melanin density as the pharmacodynamic measure of target engagement
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Not applicable.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Treatment-emergent adverse events in healthy participants
“Dersimelagon was generally well tolerated in healthy participants, with the most common TEAEs being lentigo (52.8%) and skin hyperpigmentation (50.0%) after multiple doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the incidence of TEAEs was relatively low, with most events occurring during Part A (SAD) and Part E (MAD) and the majority being mild to moderate in severity. No deaths or serious AEs were reported during any part of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: limitations of the first-in-human study
The study enrolled healthy participants rather than people with either disorder, so it does not describe clinical efficacy. Melanin density is a pharmacodynamic measure of target engagement and not a clinical outcome. The study was not designed to detect uncommon adverse events, and the transaminase elevations observed over 14 days of dosing were the basis for the intensified liver monitoring built into the later trials.